Drug Profile


Alternative Names: NM-V; Viprinex

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; Neurobiological Technologies; Nordmark Arzneimittel
  • Class Antithrombotics; Serine endopeptidases; Venoms
  • Mechanism of Action Fibrinogen inhibitors; Plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Sensorineural hearing loss
  • Market Withdrawal Heparin-induced thrombocytopenia and thrombosis syndrome; Peripheral vascular disorders; Thromboembolism
  • Discontinued Stroke

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 28 Jun 2012 Nordmark Arzneimittel plans a phase I trial for Sensorineural hearing loss in Germany (NCT01621256)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top